Clinical Trials Logo

Advanced Solid Tumours clinical trials

View clinical trials related to Advanced Solid Tumours.

Filter by:

NCT ID: NCT01163903 Completed - Clinical trials for Advanced Solid Tumours

Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours

Start date: July 2010
Phase: Phase 1
Study type: Interventional

This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been identified, six additional patients with metastatic solid tumours will be treated at the RP2D to confirm its tolerability.

NCT ID: NCT01058538 Completed - Clinical trials for Advanced Solid Tumours

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Start date: November 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed against the ED-B domain of fibronectin, one of the most important markers for neoangiogenesis, and the human cytokine interleukin-2 (IL2).